Original paper
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
Abstract
Tissue factor (TF) is a potential target in cervical cancer, as it is frequently highly expressed and associated with poor prognosis. Tisotumab vedotin, a first-in-class investigational antibody-drug conjugate targeting TF, has demonstrated encouraging activity in solid tumors. Here we report data from the cervical cancer cohort of innovaTV 201 phase I/II study (NCT02001623).Patients with recurrent or metastatic cervical cancer received...
Paper Details
Title
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
Published Date
Mar 13, 2020
Journal
Volume
26
Issue
6
Pages
1220 - 1228
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History